Incyte lands priority review for PD-1 inhibitor in anal cancer

Incyte lands priority review for PD-1 inhibitor in anal cancer

Source: 
Fierce Biotech
snippet: 

The FDA has accepted Incyte’s PD-1 inhibitor retifanlimab for priority review in patients with locally advanced or metastatic squamous cell carcinoma of the anal canal (SCAC).